To assess whether indirubin may ameliorate T‐cell dysfunction in ITP patients through normalization of PD1 and PTEN levels, we treated PBMCs from ITP patients or healthy controls with 1 μmol/L indirubin. Here, PDCD1 is linked to autoimmune thrombocytopenic purpura.